NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Centre Hospitalier Universitaire Vaudois
Conditions: Hyperparathyroidism, Primary
Interventions: there will be no intervention, this is an observational study
Countries: Switzerland
Primary hyperparathyroidism (PHPT) may induce bone loss according with the composition of the gut microbiota (GM), and particularly, on the presence of intestinal bacterial that induce T helper 17 differentiation. We will evaluate GM composition and evaluate how GM modulates immune system in patients affected by PHPT with or without skeletal involvement. Furthermore, we will unravel the causal relationship between GM composition and T cells activation. Upon success, HYPOGEUM will show that GM sequencing is a screening tool to identify PHPT that will lose bone, suggesting novel strategies with antimicrobial treatments to prevent bone loss. HYPOGEUM will yield essential data to understand and prevent skeletal complications associated with PHPT.
Sex: ALL
Age: 30 Years to 80 Years
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * diagnosis of primary hyperparathyroidism clinically established * willing and able to give written informed consent * age range 30-80 years * commitment not to use any products that may influence the study outcome * ability to understand and comply with the requirements of the study. Exclusion Criteria: * impossibility to carry out DXA * type 1 and 2 diabetes mellitus * malabsorption * alcohol abuse * renal or hepatic insufficiency * history of any malignancies * use of probiotic supplement within four weeks prior to baseline * use within the past 8 weeks of medication with known influences on the immune or skeletal system * use of antibiotics during the previous two months or frequent user of antibiotics * secondary hyperparathyroidism * use of glucocorticoids or cinacalcet * history of immunological or bone-related disorders
- Lausanne, Switzerland, Switzerland